TLIK Stock Overview
TELES Aktiengesellschaft engages in the pharmaceutical business in Germany and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Arzneiwerk AG VIDA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.95 |
| 52 Week High | €2.60 |
| 52 Week Low | €0.92 |
| Beta | 0.52 |
| 11 Month Change | 2.70% |
| 3 Month Change | -2.56% |
| 1 Year Change | -24.60% |
| 33 Year Change | -54.76% |
| 5 Year Change | -25.31% |
| Change since IPO | -99.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| TLIK | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -1.0% | 3.2% | 1.5% |
| 1Y | -24.6% | -0.8% | 4.2% |
Return vs Industry: TLIK underperformed the German Healthcare industry which returned -1.2% over the past year.
Return vs Market: TLIK underperformed the German Market which returned 4.9% over the past year.
Price Volatility
| TLIK volatility | |
|---|---|
| TLIK Average Weekly Movement | 3.8% |
| Healthcare Industry Average Movement | 3.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: TLIK has not had significant price volatility in the past 3 months.
Volatility Over Time: TLIK's weekly volatility has decreased from 11% to 4% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 39 | Sascha Knoche | www.teles.com |
TELES Aktiengesellschaft engages in the pharmaceutical business in Germany and internationally. The company offers products for oncology, neurology, ophthalmology, hemophilia, and autoimmune and infectious diseases. TELES Aktiengesellschaft was founded in 1983 and is headquartered in Berlin, Germany.
Arzneiwerk AG VIDA Fundamentals Summary
| TLIK fundamental statistics | |
|---|---|
| Market cap | €5.95m |
| Earnings (TTM) | -€2.60m |
| Revenue (TTM) | €60.60m |
0.1x
P/S Ratio-2.3x
P/E RatioIs TLIK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLIK income statement (TTM) | |
|---|---|
| Revenue | €60.60m |
| Cost of Revenue | €57.02m |
| Gross Profit | €3.58m |
| Other Expenses | €6.18m |
| Earnings | -€2.60m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Sep 30, 2024
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 5.91% |
| Net Profit Margin | -4.29% |
| Debt/Equity Ratio | -188.5% |
How did TLIK perform over the long term?
See historical performance and comparison